Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Alpha-like Protein 1 N-terminal domain (Alp1N)
- Target
- Alp1N
- Molecular classification
- Surface Antigen, Immunogenic Protein
01
Overview
The Alpha-like Protein 1 N-terminal domain (Alp1N) is an immunogenic surface protein expressed by *Streptococcus agalactiae* (Group B Streptococcus, GBS). Alp1N is a key component for GBS serotyping and vaccine design. The exposed N-terminus of Alp1 provides type-specific epitopes essential both diagnostically and therapeutically. Fusion constructs containing Alp1N are central components in next-generation maternal vaccines aiming at neonatal protection against invasive GBS disease.
- Other names
- Alp1 N-terminal domainGBS Alp1NAlpha-like protein 1 (N-terminus)Cα-like protein 1 N-terminal domain
02
Mechanism of action
Target of vaccine-induced antibodies; binding of antibodies to Alp1N prevents bacterial adhesion/invasion or opsonizes bacteria for phagocytosis.
03
Biological functions
Immune recognitionAntibody bindingSerotypingImmune evasion
04
Disease associations
Group B Streptococcus infectionNeonatal sepsisMeningitis
05
Safety considerations
Potential for incomplete protection if strain expresses serotypes not covered by vaccineRisk of vaccine-induced immune enhancement (theoretical, but needs evaluation)
Beyond the preview
Go deeper on Alpha-like Protein 1 N-terminal domain (Alp1N).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Alpha-like Protein 1 N-terminal domain (Alp1N).